{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"432.5","value":"1084.5"},{"groupId":"OG001","spread":"319.4","value":"1215.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"title":"Baseline ADC: Ongoing Chemotherapy"},{"categories":[{"measurements":[{"groupId":"OG001","spread":"134.8","value":"751.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"title":"Baseline ADC: Recent (<1yr) Chemotherapy"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"74.2","value":"547.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Baseline ADC: Never Chemotherapy"}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"description":"We first addressed an important practical limitation of the study design. Patients with new myeloma usually commenced chemotherapy imminently after their diagnosis, typically a few months before they were able to consent for the present study. Therefore, most patients had already started chemotherapy at the point of baseline novel Magnetic Resonance (MR) scan, and had received variable durations of chemotherapy at baseline and follow-up scans. We hypothesised that this may be a potential confounding factor, as more recent chemotherapy may reduce tumour cellularity and therefore increase diffusion \\[and therefore Apparent Diffusion Coefficient (ADC) measurements\\] at lytic bone lesions.\n\nIn this particular section, we analysed the difference between baseline ADC measurements in patients with new and relapsed myeloma, grouped by time elapsed since chemotherapy (ongoing, recent or never chemotherapy).","dispersionType":"Standard Deviation","groups":[{"description":"All patients with new myeloma at recruitment.","id":"OG000","title":"Group 1a: New Myeloma"},{"description":"All patients with relapsed myeloma at recruitment.","id":"OG001","title":"Group 1b: Relapsed Myeloma"}],"paramType":"MEAN","populationDescription":"Analysis included patients from Groups 1a and 1b who had a novel MR scan at baseline, with a lytic bone lesion identified amenable to ADC measurement.","reportingStatus":"POSTED","timeFrame":"At baseline","title":"Post-Hoc Analysis: Relationship Between Intercurrent Chemotherapy and Baseline Magnetic Resonance (MR) Apparent Diffusion Coefficient (ADC) Measurements","type":"POST_HOC","unitOfMeasure":"s/mm^2 (ADC measurement unit)"}